Did anyone attend the shareholders’ meeting or the investor presentation held at the end of the month? I would be very interested to know what the management said about future schedule targets.
I find the company’s communication regarding the schedules rather odd.
- Pre-validation results were supposed to come in Q4 2024, and the actual validation was supposed to start in early 2025.
- Pre-validation results were reported to come in Q1 2025.
- Pre-validation results came at the end of Q1, but they were partial and very superficial. Whole blood results were reported to be only coming in H1 2025.
- Whole blood results came on June 16th (image below), but they are also only preliminary, and results are still being collected.
- The actual validation was supposed to start in early 2025, but the company has not communicated anything about a delay or stated what has been the impediment.
The same stock exchange release implies that this is the “first phase of the study,” which leaves it unclear whether new phases are occurring before the final clinical study.
Successful completion of the first phase of this study marks another milestone as we prepare for our pivotal clinical study.